A Study of MHB039A for Advanced Solid Tumor
A phase 1/2 trial of MHB039A in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, active and no longer recruiting.
Overview
A Study of MHB039A for Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT06345482 by Minghui Pharmaceutical (Hangzhou) Ltd, with 196 participants enrolled, started 2024-04-16 and due to reach its primary completion in 2028-04-01. Interventions recorded: MHB039A.
Similar pages
not linked directly; found by shared links- TrialA Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
Shares MHB039A, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Shares MHB039A, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Shares MHB039A, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.